ScholarIQanswers from OpenAlex
Chronic Myeloid Leukemia Treatments
TopicLeading institutions, researchers & key papers
Chronic Myeloid Leukemia Treatments is a topic indexed in ScholarIQ from OpenAlex.
What is known about Chronic Myeloid Leukemia Treatments?
ScholarIQrecord summary
This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.
How many works does Chronic Myeloid Leukemia Treatments have?
ScholarIQindexed works
Chronic Myeloid Leukemia Treatments has 153 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Chronic Myeloid Leukemia Treatments?
ScholarIQopenalex
The OpenAlex for Chronic Myeloid Leukemia Treatments is on the source record.
What are the most-cited papers on Chronic Myeloid Leukemia Treatments?
ScholarIQmost cited works
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard D. Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J. Clubb, Anthony Rosenzweig, Robert Salomon, Richard A. Van Etten, Joseph Alroy, Jean‐Bernard Durand, Thomas Force
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Jiangen Gong, Antonio Costanzo, Hongqiong Yang, Gerry Melino, William G. Kaelin, Massimo Levrero, Jean Y. J. Wang
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saußele, Johan Richter, Joëlle Guilhot, Franz Gruber, Henrik Hjorth-Hansen, António Almeida, Jeroen J. W. M. Janssen, Jiřı́ Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson‐Strömberg, Joaquín Martínez‐López, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Martin C. Müller, Satu Mustjoki, Marc Berger, Alice Fabarius, Wolf‐Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, François‐Xavier Mahon, Gert J. Ossenkoppele, Maria Pagoni, Stina Söderlund, Martine Escoffre‐Barbe, Gabriel Étienne, Jolanta Dengler, Françoise Huguet, Nikolas von Bubnoff, Hana Klamová, Edgar Faber, François Guilhot, Kourosh Lotfi, Delphine Réa, Tim H. Brümmendorf, G.E. de Greef, Leif Stenke, Franck E. Nicolini, Laurence Legros, Andreas Burchert, J Voglová, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E. Westerweel
TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka, Takayuki Hoshii, Teruyuki Muraguchi, Yuko Tadokoro, Takako Ooshio, Yukio Kondo, Shinji Nakao, Noboru Motoyama, Atsushi Hirao
Where is Chronic Myeloid Leukemia Treatments research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Chronic Myeloid Leukemia Treatments is open access?
ScholarIQopen access share
67%OPEN ACCESS